Toneatti C, Saïdi Y, Meiffrédy V, Tangre P, Harel M, Eliette V, Dormont J, Aboulker JP. Experience using MedDRA for global events coding in HIV clinical trials. Contemporary Clinical Trials 2006, 27:13-22. Lien PubMed
Lévy
Y, Durier C, Lascaux A.S., Meiffrédy V, Gahéry-Ségard H, Goujard C ,
Rouzioux C, Resch M, ElHabib R, Beumont-Mauviel M, Guillet JG,
Kazatchkine M, Delfraissy JF, Aboulker JP.Sustained control of viremia following therapeutic immunization in chronically HIV-1 infected individuals. AIDS 2006, 20:405-13.Lien PubMed
Durier C, Launay O, Meiffrédy V, Saïdi Y, Salmon D, Lévy Y, Guillet J-G, Pialoux G, Aboulker J-P. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS 2006, 20:1039-1049.Lien PubMed
Samri
A, Durier C, Urrutia A, Sanchez I, Gahery-Segard H, Imbart S, Sinet M,
Tartour E, Aboulker JP, Autran B, Venet A, and the ANRS ELISpot
standardization group. Evaluation of the interlaboratory
concordance in quantification of HIV-specific T cells with a gamma
interferon enzyme-linked immunospot assay. Clin Vacc Immunol 2006, 13:684-697. Lien PubMed
Yeni
P, Cooper DA, Aboulker J-P, Babiker AG, Carey D, Darbyshire JH,
Floridia M, Girard P-M, Goodall RL, Hooker MH, Mijch A, Meiffrédy V,
Salzberger B, Antunes F, Becker M, Boukli N, Brun-Vézinet F, Churchill
D, Conway B, Chazallon C, de Wit S, Dusak B, Emery S, Flepp M, Gatell J,
Hemmer R, Law M, Loveday C, Lundgren J, Manion D, Mulcahy F, Orani A,
Pharo C, Ristola M, Sandstrom E, Schechter M, Schnittman S, Seligmann M,
Staszewski S, Stek M, Verbiest W, Weber J, Withnall R.Virological
and immunological outcomes at three years after starting antiretroviral
therapy with regimens containing non-nucleoside reverse transcriptase
inhibitor, protease inhibitor, or both in INITIO: open-label randomised
trial. The Lancet 2006, 368:287-298. Lien PubMed
Flandre P, Pinçon C, Aboulker J-P, Brun-Vézinet F, Pialoux G, Raffi F, and Descamps D.Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials. HIV Clin Trials 2006, 7:116-124.Lien PubMed
Marcelin G, Chazallon C, Gérard L, Saïdi Y, Aboulker JP, Girard PM, Calvez V, Piketty C.External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inihibitor-experienced patients. JAIDS 2006, 42:127-28.Lien PubMed
Piketty
C, Gérard L, Chazallon C, Marcelin AG, Clavel FO, Taburet AM, Calvez V,
Madelaine-Chambrin I, Molina JM, Aboulker JP, Girard PM.Salvage
therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected
patients with multiple treatment failures: randomized ANRS 107 trial. Ant Ther 2006, 11:213-21.Lien PubMed
Green
H, Gibb DM, Compagnucci A, Giacomet V, de Rossi A, Harper L, Saïdi Y,
Castelli-Gattinara G, Pillay D, Babiker A, Aboulker J-P, Lyall H,
Bacheler L, Walker AS, Debré M, Rosso R, Burger D, Della Negra M, Dunn
DT, and Giaquinto C, on behalf of the Paediatric European Network for
the Treatment of AIDS (PENTA).A randomised controlled trial of genotypic HIV drug resistance testing in HIV-1- infected children: the PERA (PENTA 8) Trial. Antiviral Therapy 2006, 11:857-67. Lien PubMed